Kane Biotech Inc.
6-1200 Waverley Street
Winnipeg
Manitoba
R3T 0P4
Canada
Tel: 204-487-7412
Fax: 204-488-9823
Website: http://www.kanebiotech.com/
Email: info@kanebiotech.com
185 articles about Kane Biotech Inc.
-
Kane Biotech to Host Investor Webinar
4/16/2024
Kane Biotech Inc. announces that it will be hosting a webinar on Thursday April 18th, 2024 at 4:15pm Eastern Time.
-
Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products
4/15/2024
Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“ Kane ”) announces that, it has completed the sale of its interest in STEM Animal Health Inc. to Dechra Veterinary Products, Inc. for US $8,000,000, plus net cash held in STEM (estimated at CND $600,000) and a working capital adjustment (estimated at CND $350,000) (the “ Transaction ”).
-
Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health
4/11/2024
Kane Biotech Inc. announces that it has reached an agreement in principle for the sale of its entire interest in STEM Animal Health Inc. to a third party multi-national pharmaceutical company on a cash-free debt-free basis for US $8,000,000, subject to adjustments in accordance with the terms of the agreement in principle, as well as other consideration including the net cash held in STEM and a working capital adjustment.
-
Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results
3/26/2024
Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results.
-
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health
3/20/2024
Kane Biotech Inc. announces today that it has extended the exclusivity period on the offer for its interest in STEM Animal Health that it announced on December 20, 2023, from March 19, 2024 until March 31, 2024.
-
Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow
3/19/2024
Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) will announce its fourth quarter and full year 2023 financial results after market close on Tuesday, March 26, 2024.
-
Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award
3/8/2024
Kane Biotech Inc. announces that at the Bioscience Association of Manitoba annual awards dinner held on March 7, 2024, Kane Biotech received the BAM Company of the Year award.
-
Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair
2/22/2024
Kane Biotech Inc. Dr. Robert Huizinga was elected as a director of the Company.
-
Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel SprayKane will introduce its unique spray gel at the Boswick Burn and Wound Care Symposium
1/31/2024
Kane Biotech Inc. announces that it has filed a patent on its revyve™ Antimicrobial Wound Gel Spray, a follow-on product to its FDA 510(k) cleared revyve™ Antimicrobial Wound Gel, and will be introducing it today at the Boswick Burn and Wound Care Symposium.
-
Kane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care Symposium
1/25/2024
Kane Biotech Inc. today announces that the Company will be presenting its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium.
-
Kane Biotech Announces Special Meeting of Shareholders - Jan 18, 2024
1/18/2024
Kane Biotech Inc. announces that on February 20, 2024, the Company will hold a special meeting of its shareholders to consider the election of Dr. Robert Huizinga as an additional director of the Company.
-
Kane Biotech Receives Offer for its Interest in STEM Animal HealthProposed transaction allows for sharpened focus on Human Health
12/20/2023
Kane Biotech Inc. announces that on December 19, 2023, it signed a non-binding offer for the sale of its interest in STEM Animal Health Inc..
-
Kane Biotech Announces Improved Third Quarter 2023 Financial Results
11/28/2023
Kane Biotech Inc. announced its third quarter 2023 financial results.
-
Kane Biotech to Release Third Quarter 2023 Financial Results on November 28, 2023 – Conference Call to Follow
11/21/2023
Kane Biotech Inc. will announce its third quarter 2023 financial results after market close on Tuesday, November 28, 2023.
-
Kane Biotech and ProgenaCare Global Launch Newly Rebranded revyve™ Antimicrobial Wound Gel at Advanced Wound Care Fall Forum
11/2/2023
Kane Biotech Inc. in partnership with ProgenaCare Global LLP announces the launch of the newly rebranded revyve™ Antimicrobial Wound Gel.
-
Kane Biotech to Exhibit at Symposium on Advanced Wound Care Fall ForumCompany to unveil new Antimicrobial Wound Gel brand developed with ProgenaCare Global
10/25/2023
Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it will be unveiling the new brand for its coactiv+™ Antimicrobial Wound Gel product (“Wound Gel”) at the Symposium on Advanced Wound Care Fall forum (“SAWC Fall”).
-
Kane Biotech Announces Second Quarter 2023 Financial Results
8/29/2023
Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its second quarter 2023 financial results.
-
Kane Biotech to Release Second Quarter 2023 Financial Results on Aug 29, 2023 – Conference Call to Follow
8/22/2023
Kane Biotech Inc. will announce its second quarter 2023 financial results after market close on Tuesday, August 29, 2023.
-
Kane Biotech Announces Private Placement Offering and Proposed Amendments to its Credit Facility
8/3/2023
Kane Biotech Inc. announces its intention to undertake a non-brokered private placement offering of up to 6,250,000 units of the Company at a price of $0.08 per Unit for gross proceeds of up to $500,000.
-
Kane Biotech Engages Research Capital to Conduct Strategic Review of STEM Animal Health
8/2/2023
Kane Biotech Inc. announced that it has engaged Research Capital Corporation as Kane’s exclusive financial advisor to conduct a strategic review process for its STEM Animal Health business division.